Stock Ticker

  • Loading stock data...

Pfizer Inc. (NYSE:PFE) To Merge Its Off-Patent Business With Mylan (NASDAQ:MYL)

There are reports indicating that Pfizer Inc. (NYSE:PFE) wants to merge its off-patent drug operations in a stock deal with generic drug maker Mylan (NASDAQ:MYL) whose market value is estimated at $9.5 billion. Pfizer to get $12 billion from sale of debt The pharmaceutical company is will spin off its new unit so that it […]

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) Announces Gregory Naeve As Chief Business Officer

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) reported that the company has appointed Gregory Naeve, Ph.D., as Chief Business Officer. Dr. Naeve will lead portfolio and product strategy and business development for the firm. The details Rick Fair, the CEO and President of Bellicum, reported that they are thrilled to welcome a leader of Dr. Naeve’s caliber and […]

The Incyte Rheumatoid Arthritis Pill Setback Poses Disagreements With FDA, As Pfizer Inc (NYSE:PFE) And Others Stand To Gain

The recent turn of events in some of the top stocks have raised eyebrows worldwide, but what Eli Lilly and Co (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) have become the highest talk cutting through the air! The two chose Friday, which as a matter of fact happens to be a market holiday to actually disclose the […]

OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) Presents Interesting Picture as a Bite-Size Buyout Candidate

OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is in an interesting phase of its existence. The company just solidified its sense of credibility in the space with a recent announcement of a productive meeting with top staffing scientists at the host hospital of the Company’s upcoming Phase 2 trial of ProscaVax for prostate cancer. That represents the first […]

Pfizer Inc. (NYSE:PFE) Wins A $40 Million Bid By BIND Therapeutics Inc (NASDAQ:BIND)

Pfizer Inc. (NYSE:PFE) was the winner of a $40 million bid by BIND Therapeutics Inc (NASDAQ:BIND). PFE succeeded at a Section 363 auction initiated by the Cambridge, Massachusetts-based biotechnology company which is selling off its assets. Among other two unidentified companies that had joined the auction Pfizer’s bid was selected as the highest and best. […]

Pfizer Inc. (NYSE:PFE) and SV Life Sciences Fund Autifony Therapeutics For Schizophrenia Research

Pfizer Inc. (NYSE:PFE) has teamed up with and SV Life Sciences to fund Autifony Therapeutics, a spin-off from GlaxoSmithKline plc (ADR) (NYSE:GSK) on research for schizophrenia treatments. The pharmaceutical industry has been extremely busy over the past year, especially with many firms merging or taking part in acquisitions. The aim of such endeavors is to […]

GlaxoSmithKline plc (ADR) (NYSE:GSK) Sells Two Vaccines to Pfizer Inc. (NYSE:PFE) to Relax Antitrust Issues

GlaxoSmithKline plc (ADR) (NYSE:GSK) has struck a deal with Pfizer Inc. (NYSE:PFE) where the latter will buy two of Glaxo’s vaccines for about $30 million. The vaccines are designed for global efforts to prevent meningococcal disease. Pfizer consented to acquire the two drugs, namely Mencevax and Nimenrix that will both be used as single doses […]

Call Buyers Active In GlaxoSmithKline plc (ADR)(NYSE:GSK)

GlaxoSmithKline plc (ADR)(NYSE:GSK) is one the U.K. stocks that have hardly fetched any attention of options traders. However, on Friday’s trading session, the call buyers are seen making position in company’s stock. The volume in GSK contracts jumped to the record level since 2007, with traders willing to pay higher premiums for bullish options compared […]

Pfizer Inc. (NYSE:PFE) Buys Stake In AM-Pharma; Option To Acquire

Pfizer Inc. (NYSE:PFE) recently purchased the biggest share percentage in AM-Pharma that is currently developing drugs for conditions such as Kidney injury. AM-Pharma is a promising Dutch Pharmaceutical company. The fact that Pfizer decided to buy some stake in the company meaning they have a lot of faith on the products from AM-Pharma. Pfizer spent […]

Pain Therapeutics, Inc. (NASDAQ:PTIE) Announces Updates to Portfolio With Respect to REMOXY

Pain Therapeutics, Inc. (NASDAQ:PTIE) has been making quite a few updates to its drug portfolio. The company announced that it would be resuming the control of REMOXY, after reaching an agreement with Pfizer Inc. (NYSE:PFE). Additionally, the company has also been conducting research on how it can use the drug to lower human abuse potential. […]

Pfizer Inc. (NYSE:PFE) Taps New R&D Leaders As Gutiérrez-Ramos Heads Back Into Biotech

Pfizer Inc. (NYSE:PFE) is in unchartered waters following the news about the exit of the company’s CEO, José-Carlos Gutiérrez-Ramos. Gutiérrez-Ramos, who is renowned for his leadership in the Bio Therapeutics research and development department in Cambridge, MA, will leave Pfizer in search of greener pastures. Word has it that he will leave the pharmaceuticals company […]

Eli Lilly and Co (NYSE:LLY) Opens a Facility At Cambridge

Eli Lilly and Co (NYSE:LLY) is looking to Cambridge to jump start its innovation engine. The company will be building a new R&D facility on the Charles River becoming the latest company to make the move. The new facility is named Lilly Cambridge Innovation Center and will start by the end of the year Kendall […]

Pfizer Inc. (NYSE:PFE) – Testing Support Band In $33.50-$34.00

Pfizer Inc. (NYSE:PFE) spent the last trading session almost flat as it ended the day with a minor loss of 0.55% but the next trading may take a different color after the announcement of the last quarterly results. The company has beat the street estimates overcoming the patent expirations and Dollar strength but the guidance […]

Drug-Maker Pfizer Inc. (NYSE:PFE) Presents Poorer Yearly Forecast For 2015-16

A top-notch US-based drug-maker Pfizer Inc. (NYSE:PFE) has cut on its yearly revenues and next-yearly profit forecast. The company has put all its blame on a stronger dollar and higher exchange ratio. A Quarterly Review In Q12015, the company notched up substantial profits, better than is potentially expected and anticipated. There has been a widespread […]

Sign Up To Get Our Latest Stocks Alerts